Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 52024M11512(01)

    Non-opposition to a notified concentration (Case M.11512 – OTPP / NORDIC CAPITAL / ADVANZ PHARMA)

    C/2024/4510

    OJ C, C/2024/4278, 3.7.2024, ELI: http://data.europa.eu/eli/C/2024/4278/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    ELI: http://data.europa.eu/eli/C/2024/4278/oj

    European flag

    Official Journal
    of the European Union

    EN

    C series


    C/2024/4278

    3.7.2024

    Non-opposition to a notified concentration

    (Case M.11512 – OTPP / NORDIC CAPITAL / ADVANZ PHARMA)

    (Text with EEA relevance)

    (C/2024/4278)

    On 24 June 2024, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

    in the merger section of the ‘Competition policy’ website of the Commission (https://competition-cases.ec.europa.eu/search). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

    in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32024M11512. EUR-Lex is the online point of access to European Union law.


    (1)   OJ L 24, 29.1.2004, p. 1.


    ELI: http://data.europa.eu/eli/C/2024/4278/oj

    ISSN 1977-091X (electronic edition)


    Top